New Hope To Outsmart Lung Cancer
AI & Genomics Advances
That Make Lung Cancer Screening Convenient and Effective With a Single Blood Draw
Introducing
SPOT-MAS Lung
A smart blood-based test for routine lung cancer screening by applying AI to check DNA from lung cells.
90%Sensitivity(1)
92%Specificity(1)
- What is SPOT-MAS Lung test?
- Why should we care?
- Who should consider starting SPOT-MAS Lung cancer screening?
- What do results mean?
Sources:
(1) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Lung Cancer Detection (January 11, 2025). dx.doi.org/10.2139/ssrn.5Enhance094108
01
What is SPOT-MAS Lung test?
A non-invasive blood test to detect cancer early
SPOT-MAS Lung is a cancer screening blood test that integrates multiple AI techniques to analyze circulating tumor DNA (ctDNA) deprived from lung cells. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening(1).
Only requires a blood draw tube (10ml)
Next-Generation Sequencing
Multimodal AI
90%
Sensitivity
92%
Specificity
Sources:
(1) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Lung Cancer Detection (January 11, 2025). dx.doi.org/10.2139/ssrn.5Enhance094108
02
Why should we care?
Asia is the most impacted region worldwide(2)
63.1%
of newly diagnosed lung cancers
62.9%
of lung cancer deaths
Lung Cancer Screening Gaps in Asia
Only the highest-risk population (heavy smokers) is advised to undergo low-dose CT scans routinely to minimize the risk of radiation-induced cancer during scanning rounds(3). Moreover, CT devices are not easily accessible for many people due to geographical and economic barriers.
50%
of lung cancer cases in never-smokers may be missed under current screening guidelines and eligibility criteria(4)
83%
of women with lung cancer in South-East Asia are never-smokers, making them particularly vulnerable(5)
33%
of lung cancer deaths occur in non-smokers, highlighting the need for broader screening strategies(6)
Sources:
(2) Chiu, C., & Yang, P. (2024). EClinicalMedicine (3) Pozzessere, C. et al. (2023). Tomography (4) Kerpel-Fronius, A., et al. (2021). Journal of Thoracic Oncology (5) Barta, J. A. et al. (2019). Annals of Global Health (6) GLOBOCAN (2020)
03
Who should consider starting SPOT-MAS Lung cancer screening?
- Smoking history ≥20 pack-years or quit smoking <15 years ago
- Exposure to secondhand smoke, radon, air pollution, or occupational/environmental
- First-degree relatives with lung cancer
- Diagnosed with lung disease: COPD, pulmonary fibrosis
- Exposure to carcinogens: arsenic, asbestos, beryllium, cadmium, chromium, coal smoke, diesel exhaust, nickel, silica, soot, and uranium
- Suspected symptoms (Persistent cough ≥ 3 weeks…)
- Lung lesions of unclear nature OR classified as benign/possibly benign
Adults aged 50 years and older, particularly those at elevated risk for cancer.(7),(8),(9),(10)
Sources:
(7) U.S. Preventive Services Task Force Recommendation for Lung Cancer Screening. (8) The Japan Lung Cancer Society: Lung Cancer Screening Guidelines (9) Infante, M. V., & Cardillo, G. (2020). European Respiratory Journal (10) Kerpel-Fronius et al. (2021). Journal of Thoracic Oncology
04
What do results mean?
Negative:
No ctDNA signal detected
ctDNA was not detected at the time SPOT-MAS test is conducted. This test provides a snapshot of the blood at the time of collection and does not predict for future cancer risks.
Next step
Continue with the SPOT-MAS test annually or other screens as recommended by your doctor. Do not ignore cancer signs or symptoms if they occur, as this could lead to a delayed diagnosis.
Positive:
ctDNA signal detected
ctDNA signal associated with tumor cells was detected in the blood.
Next step
As the SPOT-MAS test is a screening test, a confirmatory imaging test is required to confirm if cancer is truly present. Your doctor will advise you on the required following tests.
Testing process
Request the test through your primary care doctor. A prescription and 10ml blood collection are required.
Your extracted DNA from the plasma will be sequenced by Next-generation ctDNA technology to analyze multi-feature of DNA.
Receive your ctDNA signal analysis results after 20 working days from the time sample is received at Gene Solutions Genomics Singapore laboratory.
SPOT-MAS Portfolio
Explore More Cancer Screening Options with SPOT-MAS:
| Test | Scope | AI Technology |
|---|---|---|
Multiple features of 10 cancer types:
| Multi AI machine learning and deep learning models | |
| Multiple lung-specific features | Cell-free Multiomic ATLAS | |
SPOT-MAS CRC | Multiple colorectum-specific features |
(*) First multi-cancer early detection test to complete clinical validation in Asia on
